0.7031
price up icon4.94%   0.0331
 
loading
Xilio Therapeutics Inc stock is traded at $0.7031, with a volume of 361.51K. It is up +4.94% in the last 24 hours and up +0.44% over the past month. Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
See More
Previous Close:
$0.67
Open:
$0.66
24h Volume:
361.51K
Relative Volume:
0.66
Market Cap:
$36.44M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2375
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
-0.83%
1M Performance:
+0.44%
6M Performance:
-24.40%
1Y Performance:
-21.12%
1-Day Range:
Value
$0.656
$0.71
1-Week Range:
Value
$0.6406
$0.73
52-Week Range:
Value
$0.615
$1.70

Xilio Therapeutics Inc Stock (XLO) Company Profile

Name
Name
Xilio Therapeutics Inc
Name
Phone
617-833-1027
Name
Address
828 WINTER STREET, WALTHAM
Name
Employee
73
Name
Twitter
Name
Next Earnings Date
2025-08-08
Name
Latest SEC Filings
Name
XLO's Discussions on Twitter

Compare XLO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
XLO
Xilio Therapeutics Inc
0.7031 36.61M 0 -81.22M -74.41M -2.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-06-25 Initiated Leerink Partners Outperform
Dec-21-22 Initiated Chardan Capital Markets Buy
Jan-10-22 Initiated H.C. Wainwright Buy
Nov-16-21 Initiated Cowen Outperform
Nov-16-21 Initiated Guggenheim Buy
Nov-16-21 Initiated Morgan Stanley Overweight
Nov-16-21 Initiated Raymond James Outperform
View All

Xilio Therapeutics Inc Stock (XLO) Latest News

pulisher
Aug 20, 2025

Technical Models Suggest Xilio Therapeutics Inc. May Rebound Soon2025 Market Overview & Expert Verified Movement Alerts - mustnews.co.kr

Aug 20, 2025
pulisher
Aug 19, 2025

Xilio Therapeutics Reports Q2 Earnings with Promising Pipeline Progress and Financial Results - AInvest

Aug 19, 2025
pulisher
Aug 18, 2025

Xilio Therapeutics Reports Strong Pipeline Progress and Financial Results - TipRanks

Aug 18, 2025
pulisher
Aug 18, 2025

Xilio Therapeutics Q2 2025 Earnings Miss Fails to Deliver, but Short-Term Price Action Shows Promise - AInvest

Aug 18, 2025
pulisher
Aug 17, 2025

Xilio Therapeutics Q2 2025 Earnings Miss: Mixed Market Impact Amid Biotech Sector Resilience - AInvest

Aug 17, 2025
pulisher
Aug 16, 2025

Does Xilio Therapeutics Inc. align with a passive investing strategy2025 Price Action Summary & Low Risk Investment Opportunities - thegnnews.com

Aug 16, 2025
pulisher
Aug 16, 2025

Xilio Therapeutics Second Quarter 2025 Earnings: US$0.16 loss per share (vs US$0.32 loss in 2Q 2024) - Yahoo Finance

Aug 16, 2025
pulisher
Aug 16, 2025

Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Clover Health Investments (CLOV) and Xilio Therapeutics (XLO) - The Globe and Mail

Aug 16, 2025
pulisher
Aug 15, 2025

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates - MSN

Aug 15, 2025
pulisher
Aug 15, 2025

Xilio Therapeutics shares fall 1.27% after-hours following Q2 pipeline progress and business updates. - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Xilio Revenue Jumps 246 Percent in Q2 - AOL.com

Aug 15, 2025
pulisher
Aug 15, 2025

Xilio Therapeutics 2025 Q2 Earnings Improved EPS Amid Wider Net Loss - AInvest

Aug 15, 2025
pulisher
Aug 14, 2025

Xilio Therapeutics Q2 Earnings Beat Expectations, Revenue Doubles to $8.084M. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Xilio Therapeutics shares fall 2.52% intraday after announcing updated Phase 2 data for vilastobart. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Xilio Therapeutics Reports Q2 Loss, Misses Revenue Estimates: Stock Expected to Underperform Market - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Xilio Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2025
pulisher
Aug 14, 2025

Xilio Therapeutics, Inc. SEC 10-Q Report - TradingView

Aug 14, 2025
pulisher
Aug 14, 2025

Xilio Therapeutics Q2 2025 Financial Results and Business Updates - TradingView

Aug 14, 2025
pulisher
Aug 14, 2025

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results - GlobeNewswire

Aug 14, 2025
pulisher
Aug 14, 2025

Cancer Drug Breakthrough: Xilio's Vilastobart Delivers Strong Results with Fewer Side Effects - Stock Titan

Aug 14, 2025
pulisher
Aug 09, 2025

Heatmap analysis for Xilio Therapeutics Inc. and competitorsTrade Plan With Low Risk High Return - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Brokers Issue Forecasts for XLO Q2 Earnings - Defense World

Aug 09, 2025
pulisher
Aug 09, 2025

Advanced analytics toolkit walkthrough for Xilio Therapeutics Inc.Free Stock Market Watch With Alerts - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Analyzing drawdowns of Xilio Therapeutics Inc. with statistical toolsAsset Allocation Summary With Future Outlook - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Leerink Partners Initiates Coverage on Xilio Therapeutics with Outperform Rating, Sets Price Target of $2.00 - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

How to use Fibonacci retracement on Xilio Therapeutics Inc.Momentum Entry Alerts with Risk Control - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Using Bollinger Bands to evaluate Xilio Therapeutics Inc.Free High Conviction Intraday Stock Signals - Newser

Aug 09, 2025
pulisher
Aug 08, 2025

Leerink Partners Maintains Xilio Therapeutics(XLO.US) With Buy Rating, Maintains Target Price $2 - 富途牛牛

Aug 08, 2025
pulisher
Aug 08, 2025

Leerink Partners Begins Coverage on Xilio Therapeutics (NASDAQ:XLO) - Defense World

Aug 08, 2025
pulisher
Aug 07, 2025

Xilio Therapeutics (XLO) Projected to Post Quarterly Earnings on Thursday - Defense World

Aug 07, 2025
pulisher
Aug 06, 2025

Leerink Partners Initiates Coverage on Xilio Therapeutics with Outperform Rating - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Leerink Partners Initiates Xilio Therapeutics(XLO.US) With Buy Rating, Announces Target Price $2 - 富途牛牛

Aug 06, 2025
pulisher
Aug 06, 2025

Xilio Therapeutics shares rise 4.95% premarket after Leerink Partners initiates coverage with an Outperform rating. - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Leerink Partners Initiates Xilio Therapeutics at Outperform With $2 Price Target - MarketScreener

Aug 06, 2025
pulisher
Aug 06, 2025

Leerink Partners initiates coverage on Xilio Therapeutics stock with Outperform rating - Investing.com India

Aug 06, 2025
pulisher
Aug 06, 2025

Leerink Partners initiates coverage on Xilio Therapeutics stock with Outperform rating By Investing.com - Investing.com South Africa

Aug 06, 2025
pulisher
Aug 04, 2025

Xilio Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView

Aug 04, 2025
pulisher
Aug 04, 2025

Xilio Therapeutics shares rise 2.77% intraday after Catalyst Pharmaceuticals appoints new board member. - AInvest

Aug 04, 2025
pulisher
Aug 03, 2025

When is Xilio Therapeutics Inc. stock expected to show significant growthCapitalize on market shifts before others do - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What institutional investors are buying Xilio Therapeutics Inc. stockUnlock powerful investment tools for free - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Xilio Therapeutics Inc. stock price move sharplyAchieve consistent profits with smart trading - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Xilio Therapeutics Inc. a growth stock or a value stockAchieve rapid wealth accumulation through smart investing - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

Why is Xilio Therapeutics Inc. stock attracting strong analyst attentionAccelerated wealth expansion - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What are Xilio Therapeutics Inc. company’s key revenue driversMaximize gains with proven stock analysis - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What is Xilio Therapeutics Inc. company’s growth strategyIdentify winners with top-tier analysis - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What are the latest earnings results for Xilio Therapeutics Inc.Maximize returns with effective portfolio management - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Xilio Therapeutics Inc. Stock Analysis and ForecastNavigate the market with precision tools - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

MACD Cross Could Confirm Trend in Xilio Therapeutics Inc.Alpha Driven Watchlist With Alerts Published - metal.it

Aug 02, 2025
pulisher
Aug 02, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Aug 02, 2025
pulisher
Aug 01, 2025

What is the risk reward ratio of investing in Xilio Therapeutics Inc. stockMarket Forecast Data Feed From AI Tools - Jammu Links News

Aug 01, 2025
pulisher
Aug 01, 2025

Xilio Therapeutics Awards $87K Worth of Stock Options in Key Employee Inducement Plan - Stock Titan

Aug 01, 2025

Xilio Therapeutics Inc Stock (XLO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Xilio Therapeutics Inc Stock (XLO) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Shannon James Samuel
Director
Jun 17 '25
Buy
0.69
25,000
17,215
70,000
Russo Rene
PRESIDENT AND CEO
Jun 16 '25
Buy
0.68
36,289
24,680
281,172
Frankenfield Christopher James
Chief Financial Officer
Jan 02 '25
Sale
0.98
6,954
6,841
12,421
Brennan Kevin M.
SVP, FINANCE AND ACCOUNTING
Jan 02 '25
Sale
0.98
1,803
1,774
3,197
GILEAD SCIENCES, INC.
10% Owner
Dec 18 '24
Buy
1.04
1,759,978
1,830,377
9,105,451
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):